drugset
drugset / Trial / NCT06993870

Phase I Study of HBT-708 for Patients With Advanced Solid Tumors

NCT06993870 ↗

Phase 1 Recruiting 60 enrolled Shenyang Sunshine Pharmaceutical Co., LTD.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study will be to evaluate the safety, tolerability, and inital efficacy of HBT-708 in subjects with advanced solid tumors.

Timeline

Start
2025-06-16
Primary completion
2026-03-01
Completion
2027-06-28

Drugs

EvaluationDrugModalityDoseRoute
Subject HBT-708 Unknown — Intravenous

Indications

cancer